Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

Novavax's growth relies on Sanofi royalties and COVID/flu vaccines, lacking innovation and clear catalysts. Click here to ...

Novavax Inc. closed 61.37% short of its 52-week high of $17.81, which the company reached on July 26th.

Novavax Inc. closed 60.86% short of its 52-week high of $17.81, which the company reached on July 26th.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Shares for Novavax swelled by more than 130% Friday morning, after the biotech firm announced a $1.4 billion deal with Sanofi to commercialize its Covid vaccine and develop a new combination shot ...

Novavax expects revenue of $4 billion to $5 billion this year in global sales, Trizzino said, noting "this is not just a pandemic question, it's an ongoing vaccination question." ...

Novavax was authorized by the FDA for use in adults and children 12 and older, so younger kids can't get this vaccine. But for most adults, which COVID vaccine you should choose depends on your ...

The same can’t be said about the Novavax one. The Novavax Covid-19 vaccine includes a combination of the actual SARS-CoV-2 spike protein and what’s called the Matrix-M adjuvant.

Novavax COVID vaccine will still save lives, experts say, even with limited supply. There are still more than 26 million American adults who are unvaccinated.

The biotechnology company Novavax plans to submit complete data to the US Food and Drug Administration soon for possible emergency use authorization of its coronavirus vaccine, CEO Stanley Erck ...